Have a feature idea you'd love to see implemented?
Let us know!
TBPH Theravance Biopharma Inc
Price (delayed)
$9.61
Market cap
$472.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.03
Enterprise value
$493.33M
Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives
Highlights
TBPH's revenue is up by 16% year-on-year
The gross profit has grown by 16% YoY
The net income has grown by 13% YoY but it has contracted by 8% from the previous quarter
Theravance Biopharma's EPS has shrunk by 69% YoY and by 10% QoQ
TBPH's equity is down by 25% year-on-year and by 4.1% since the previous quarter
Key stats
What are the main financial stats of TBPH
Market
Valuations
Earnings
Shares outstanding
49.17M
Market cap
$472.56M
Enterprise value
$493.33M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.53
Price to sales (P/S)
7.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.81
Revenue
$63.19M
EBIT
-$38.17M
EBITDA
-$31.7M
Free cash flow
-$12.31M
Per share
Balance sheet
Liquidity
EPS
-$1.03
Free cash flow per share
-$0.25
Book value per share
$3.79
Revenue per share
$1.29
TBVPS
$7.26
Total assets
$356.11M
Total liabilities
$170.45M
Debt
$44.98M
Equity
$185.65M
Working capital
$93.05M
Debt to equity
0.24
Current ratio
4.97
Quick ratio
4.65
Net debt/EBITDA
-0.66
Margins
Efficiency
Dividend
EBITDA margin
-50.2%
Gross margin
100%
Net margin
-78.2%
Operating margin
-69.6%
Return on assets
-13.4%
Return on equity
-24.8%
Return on invested capital
-10.9%
Return on capital employed
-11.5%
Return on sales
-60.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TBPH stock price
How has the Theravance Biopharma stock price performed over time
Intraday
-3.61%
1 week
0.42%
1 month
10.97%
1 year
-6.52%
YTD
-14.5%
QTD
19.23%
Financial performance
How have Theravance Biopharma's revenue and profit performed over time
Revenue
$63.19M
Gross profit
$63.19M
Operating income
-$43.99M
Net income
-$49.4M
Gross margin
100%
Net margin
-78.2%
Theravance Biopharma's operating margin has increased by 44% YoY but it has decreased by 3% QoQ
The operating income is up by 35% YoY but it is down by 5% QoQ
Theravance Biopharma's net margin has increased by 25% YoY but it has decreased by 6% QoQ
TBPH's revenue is up by 16% year-on-year
Growth
What is Theravance Biopharma's growth rate over time
Valuation
What is Theravance Biopharma stock price valuation
P/E
N/A
P/B
2.53
P/S
7.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.81
Theravance Biopharma's EPS has shrunk by 69% YoY and by 10% QoQ
TBPH's equity is down by 25% year-on-year and by 4.1% since the previous quarter
The price to book (P/B) is 15% higher than the last 4 quarters average of 2.2
The P/S is 42% lower than the 5-year quarterly average of 12.9 and 3.1% lower than the last 4 quarters average of 7.7
TBPH's revenue is up by 16% year-on-year
Efficiency
How efficient is Theravance Biopharma business performance
The ROE has contracted by 46% YoY and by 16% from the previous quarter
Theravance Biopharma's return on sales has increased by 41% YoY but it has decreased by 4.9% QoQ
The ROIC has grown by 30% YoY but it has contracted by 8% from the previous quarter
The company's return on assets fell by 18% YoY and by 13% QoQ
Dividends
What is TBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TBPH.
Financial health
How did Theravance Biopharma financials performed over time
Theravance Biopharma's total assets is 109% more than its total liabilities
TBPH's current ratio is down by 22% year-on-year and by 4.4% since the previous quarter
The company's quick ratio fell by 22% YoY and by 4.1% QoQ
Theravance Biopharma's debt is 76% lower than its equity
TBPH's equity is down by 25% year-on-year and by 4.1% since the previous quarter
The debt to equity rose by 14% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.